Author:
Hren M. Grace,Piontkowski Austin,Khattri Saakshi
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Kurzinski K, Torok KS (2011) Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 55(2):157–164. https://doi.org/10.1016/j.cyto.2011.04.001
2. Bantz SK, Zhu Z, Zheng T (2014) The atopic March: progression from atopic dermatitis to allergic Rhinitis and Asthma. J Clin Cell Immunol 5(2):202. https://doi.org/10.4172/2155-9899.1000202
3. Gasparini G, Cozzani E, Parodi A (2020) Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. Cytokine 125:154799. https://doi.org/10.1016/j.cyto.2019.154799
4. Ivert LU, Wahlgren CF, Lindelöf B, Dal H, Bradley M, Johansson EK (2021) Association between atopic dermatitis and autoimmune diseases: a population-based case-control study. Br J Dermatol 185(2):335–342. https://doi.org/10.1111/bjd.19624
5. Schleicher S Clinical trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma. ClinicalTrials.gov identifier: NCT04200755. Updated 2022-11-03. Accessed 2024-5-16. https://clinicaltrials.gov/study/NCT04200755